Multiple sclerosis (MS) is a chronic, often disabling disease that attacks the central nervous system. The management of patients with MS is highly complex, and the development of disease-modifying therapies (DMTs) has dramatically altered the treatment paradigm. Clinicians need to be updated on new evidence-based recommendations on the use of DMTs from the American Academy of Neurology Guidelines released in 2018. Another important aspect of caring for patients with MS is communication. Patients must be not only educated about their disease and treatment options, but also engaged in conversations about their risk tolerance, quality of life—including symptoms that they are experiencing—and any concerns they may have regarding their care. Shared decision-making is a model of two-way communication between a patient and a provider with established ability to improve a patient’s satisfaction of care. In this CME/CNE activity, MS Forum®VI, current treatment guidelines, gender-based issues, environmental factors, and comorbidities in MS will be discussed alongside the safety, efficacy, and use of current DMTs. In addition, the program will include rapid TED-like didactic presentations, video segments of a patient’s perspective of MS, and a rapid-fire panel addressing controversial topics in MS.

Activity Chair

Patricia K. Coyle, MD, FAAN, FANA
Professor and Interim Chair (Clinical Affairs)
Department of Neurology
Director
Multiple Sclerosis Comprehensive Care Center
Stony Brook University Medical Center
Stony Brook, NY

Steering Committee

Bruce A. Cohen, MD, FAAN, FANA, FACP
Professor of Neurology
Northwestern University
Feinberg School of Medicine
Director
Northwestern Comprehensive Multiple Sclerosis Program
Chicago, IL

Clyde E. Markowitz, MD
Associate Professor of Neurology
Director, Multiple Sclerosis Center
Hospital of the University of Pennsylvania
Perelman School of Medicine
Philadelphia, PA

Claire S. Riley, MD
Assistant Professor of Neurology
Director of the Columbia University Multiple Sclerosis Clinical Care and Research Center
Department of Neurology, Columbia University
New York, NY

Guest Faculty

Elena Grebenciucova, MD
Assistant Professor of Neurology
Northwestern University
Chicago, IL

Marwa Kaisey, MD
Assistant Professor of Neurology
Multiple Sclerosis and Neuroimmunology Program
Cedars-Sinai Medical Center
Los Angeles, CA

Stephen Krieger, MD, FAAN
Associate Professor of Neurology
Icahn School of Medicine at Mount Sinai
New York, NY

Michael Sy, MD, PhD
Assistant Professor
University of California, Irvine
Irvine, CA

Agenda

7:30 AM
Registration and Breakfast

8:00 AM
Introduction and Pretest

8:10 AM
Updates in DMTs: Clinical and Practical Review

8:40 AM
New and Promising Advances in MS

9:00 AM
Clinical Case: Optimal Initial Treatment Selection

9:10 AM
Gender-based Issues in MS

9:30 AM
Clinical Case: Management of MS in Pregnancy and Pre/Postnatal Care

9:40 AM
Posttest and Question and Answer with Panel Discussion

10:00 AM
Break

10:15 AM
TED Talks in MS: What You’ve Been Asking About

11:15 AM
Updates in Progressive MS: Recognition and Management

11:40 AM
Clinical Case: Progressive MS

11:50 AM
Environmental Factors and Comorbidities in MS

12:10 PM
Patient Perspectives in MS

12:30 PM
Rapid-Fire Controversies in MS

12:50 PM
Clinical Case: Bringing It All Together

1:00 PM
Posttest and Question and Answer with Panel Discussion

1:15 PM
Conclusion

Learning Objectives

Upon successful completion of this activity, participants should be better able to:

Physicians and Nurses

• Evaluate the latest clinical and/or real-world evidence regarding available and emerging DMTs for MS management.

• Assess the burden of comorbidities for patients with MS and implications for treatment, medication management, and quality of life.

• Examine emerging clinical trends and controversies in MS that may impact future clinical decision making.

• Incorporate appropriate shared decision-making strategies to engage patients with MS in their own care.

Physicians Only

• Identify patients with RRMS or progressive MS in a timely manner to ensure appropriate intervention.

• Select treatment for patients with RRMS or progressive MS based on the latest clinical advances, patient risk, and evidence-based recommendations.

  
  

Target Audience

The intended audience for this activity is neurologists, neurology nurses, and other health care professionals involved in the management of patients with MS.

Other Dates and Locations

More information on other dates and locations that are a part of this series can be found as follows:

• OCTOBER 26 - CHICAGO, IL

• NOVEMBER 2 - NEWPORT BEACH, CA

• NOVEMBER 9 - PHILADELPHIA, PA

• DECEMBER 7 - WASHINGTON, DC
  

This continuing education activity is provided by Vindico Medical Education.

This activity is supported by educational grants from Biogen; Celgene Corporation; EMD Serono, Inc.; Genentech, Inc.; and Sanofi Genzyme.

Endorsed by The Consortium of Multiple Sclerosis Centers.

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Vindico Medical Education designates this live activity for a maximum of 5.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Vindico Medical Education, LLC, is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Vindico Medical Education will provide 5.0 contact hours for nurses.

In accordance with the Accreditation Council for Continuing Medical Education and American Nurses Credentialing Center’s Standards for Commercial Support, all planners, teachers, and authors involved in the development of CME/CNE content are required to disclose to the accredited provider their relevant financial relationships. Relevant financial relationships will be disclosed to the activity audience.

There is no non-commercial support for this activity.

Education activities are distinguished as separate from endorsement of commercial products. When commercial products are displayed, participants will be advised that accredited status as a provider refers only to its continuing education activities and does not imply ANCC Commission on Accreditation endorsement of any commercial products.

Faculty, topics, program schedule, and credit hours are subject to change. Audiotaping or videotaping is prohibited without written permission from the program committee.

MIPS Qualifying Activity:
Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS). Participants who successfully complete the activity and its performance assessment will receive printable documentation of successful completion for MIPS self-reporting.